Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...
Digital-Intelligent Transformation of China’s Pharmaceutical Industry: 2025-2030 Plan Unveiled
China’s Ministry of Industry and Information Technology, Ministry of Commerce, National Health Commission (NHC), and...
Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million...
Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline
Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...
Amgen Announces $900M Investment to Expand Ohio Manufacturing
US biotech leader Amgen (NASDAQ: AMGN) announced a USD 900 million investment to expand its...
Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...
Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...
Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC
China-based Akeso, Inc. (HKG: 9926) announced that its supplementary New Drug Application (sNDA) for ivonescimab,...
Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China
China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...
Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...
Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...
Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis
China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...
TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis
China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...
MicroPort Scientific’s MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), through its French subsidiary MicroPort Cardiac...
AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment
US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...
GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval
Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...
Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug
France-based Innate Pharma SA has announced a significant adjustment to its 2016 research and licensing...
Medtronic Submits 510(k) Applications for Interoperable Diabetes Management System
US-Irish firm Medtronic plc (NYSE: MDT) has submitted twin 510(k) applications to the U.S. Food...
Thermo Fisher Announces $2 Billion US Investment to Strengthen Life Sciences Infrastructure
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a USD 2...